Navigating Novo Nordisk’s acquisition of Catalent

In this episode of the Molecule to Market podcast, NorthX Biologics CEO Janet Hoogstraate was invited to discuss the implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector, in a panel together with other industry experts:

• Dirk Lange, CEO at Pyramid Labs
• Brett Alderson, President & Site Leader at NovaCina
• John Cameron, Director, Global Injectables Platform at Corden Pharma

Podcast host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:

• Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilities
• Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs
• Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments
• Strategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector

With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk’s strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.

Listen to the podcast here:
Spotify: https://ow.ly/I5ET50PlzP0
Apple: https://ow.ly/8kNF50PlzOZ
Amazon: https://ow.ly/M3WI50PlzP1

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.